News & Updates
ELIAS Animal Health Launches Clinical Trial Of Cancer Immunotherapy Treatment For Canine Oral Melanoma
Olathe, Kan., August 31, 2021 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a pilot study of its adoptive T cell therapy combined with surgery and radiotherapy, if indicated, for dogs diagnosed with oral malignant melanoma, a highly metastatic disease and the most common form of oral cancer seen in dogs. Melanoma is widely believed to be chemo-resistant and in this study the adoptive T cell therapy will be administered instead of chemotherapy. This clinical trial will enroll dogs that have been newly diagnosed with oral melanoma [...]
Long-term bone cancer survivor and ECI® patient featured on local news
Ruby the Greyhound was diagnosed with osteosarcoma in December 2016 and began the ELIAS cancer immunotherapy (ECI®). Today, Ruby is thriving and her story was recently featured on a Kansas City local news channel. Learn more about Ruby, one of five long-term survivors from the ELIAS preliminary study. Read the story
ELIAS Animal Health Expands Clinical Trial of Immunotherapy Treatment for Cancer in Dogs
Ten sites now participating in trial of alternative treatment to chemotherapy for canine osteosarcoma Olathe, Kansas, Nov. 12, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces that 10 investigation sites across the U.S. are now participating in the pivotal trial of ELIAS cancer immunotherapy (ECI®). This marks an expansion of the study ELIAS initiated in May to pursue licensure of ECI treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. The geographical areas served by the clinical trial [...]